

FOI 3796

16th June 2026

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available?

Name of medicine	Number patients treated
1.1 Avelumab (Bavencio)	
1.2 Atezolizumab (Tecentriq)	
1.3 Pembrolizumab (Keytruda)	
1.4 Nivolumab (Opdivo)	
1.5 Durvalumab (Imfinzi)	
1.6 Erdafitinib (Balversa)	
1.7 Enfortumab vedotin (Padcev)	
1.8 Cisplatin	
1.9 Carboplatin	
1.10 Gemcitabine	

Response:

Name of medicine	Number patients treated
1.1 Avelumab (Bavencio)	<5*
1.2 Atezolizumab (Tecentriq)	6
1.3 Pembrolizumab (Keytruda)	30

1.4 Nivolumab (Opdivo)	<5
1.5 Durvalumab (Imfinzi)	10
1.6 Erdafitinib (Balversa)	-
1.7 Enfortumab vedotin (Padcev)	-
1.8 Cisplatin	<5*
1.9 Carboplatin	23
1.10 Gemcitabine	20

*The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.

Q2. How many patients were treated with avelumab (Bavencio) for the following types of cancer in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available?

Name of monotherapy or combination	Number patients treated
Merkel Cell Carcinoma (ICD-10 codes = C4A* and/or morphology code = 8247/3)	
Urothelial Carcinoma (ICD-10 codes = C65*, C66*, C67* and/or morphology code = 8120*, 8130*, 8131/3, 8122/3, 8031/3)	
Renal Cell Carcinoma (C64*)	
Other types of tumour	

Response: This information is not recorded centrally and therefore retrieving it would involve a manual search of individual patient records. As such we cannot provide this information as the cost of locating and retrieving the information exceeds the "appropriate limit" as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of individual patient records would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

In addition, it would not be appropriate to search through individual patient records for the purposes for responding to a FOI request, there would be no patient expectation that medical records would be used in this way.

Furthermore, under Section 16 of the Freedom of Information Act, we can advise that it would require an extensive manual review of all admissions just to ascertain if information relevant to your request is held. As such, we advise that there is no way to refine this request to bring it within the appropriate limit.

Q3. How many patients with Renal Cell Carcinoma (RCC) were treated with the following medicines, in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available?

Name of monotherapy or combination	Number treated	patients
3.1 Avelumab + Axitinib		

Response: This information is not recorded centrally and therefore retrieving it would involve a manual search of individual patient records. As such we cannot provide this information as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of individual patient records would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

In addition, it would not be appropriate to search through individual patient records for the purposes for responding to a FOI request, there would be no patient expectation that medical records would be used in this way.

Furthermore, under Section 16 of the Freedom of Information Act, we can advise that it would require an extensive manual review of all admissions just to ascertain if information relevant to your request is held. As such, we advise that there is no way to refine this request to bring it within the appropriate limit.

Q4. How many patients with Urothelial Carcinoma (UC) were treated with the following medicines, in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available?

Name of monotherapy or combination	Number treated	patients
4.1 Avelumab Monotherapy Maintenance		
4.2 Atezolizumab		
4.3 Pembrolizumab Monotherapy		
4.4 Pembrolizumab + Enfortumab vedotin		

4.5 Nivolumab Monotherapy		
4.6 Nivolumab + Cisplatin + Gemcitabine		
4.7 Durvalumab Monotherapy Maintenance		
4.8 Durvalumab + Gemcitabine + Cisplatin		
4.9 Carboplatin+ Gemcitabine		
4.10 Paclitaxel Monotherapy		
4.11 Carboplatin + Paclitaxel		
4.12 Cisplatin + Gemcitabine		

Response: This information is not recorded centrally and therefore retrieving it would involve a manual search of individual patient records. As such we cannot provide this information as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of individual patient records would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

In addition, it would not be appropriate to search through individual patient records for the purposes for responding to a FOI request, there would be no patient expectation that medical records would be used in this way.

Furthermore, under Section 16 of the Freedom of Information Act, we can advise that it would require an extensive manual review of all admissions just to ascertain if information relevant to your request is held. As such, we advise that there is no way to refine this request to bring it within the appropriate limit.

Q5. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available?

Name of medicine	Number treated	patients
5.1 Aflibercept – (Zaltrap only)		
5.2 Bevacizumab		
5.3 Cetuximab		
5.4 Encorafenib		
5.5 Fruquintinib		
5.6 Nivolumab		

5.7 Panitumumab		
5.8 Pembrolizumab		
5.9 Regorafenib		
5.10 Trifluridine + Tipiracil (Lonsurf)		

Response:

Name of medicine	Number treated	patients
5.1 Aflibercept – (Zaltrap only)	-	
5.2 Bevacizumab	15	
5.3 Cetuximab	16	
5.4 Encorafenib	<5*	
5.5 Fruquintinib	<5*	
5.6 Nivolumab	Already answered Q1	
5.7 Panitumumab	-	
5.8 Pembrolizumab	Already answered Q1	
5.9 Regorafenib	-	
5.10 Trifluridine + Tipiracil (Lonsurf)	5	

*The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition, the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.

Q6. How many patients were treated for Colorectal Cancer (ICD-10 codes C18*, C19*, C20*, D010, D011, D012) with the following medicines in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available?

Name of medicine		Number patients with CRC treated
6.1 Bevacizumab		
6.2 Cetuximab		
6.3 Encorafenib		
6.4 Nivolumab		
6.5 Pembrolizumab		
6.6 Regorafenib		
6.7 Trifluridine + Tipiracil (Lonsurf)		

Response: This information is not recorded centrally and therefore retrieving it would involve a manual search of individual patient records. As such we cannot provide this information as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of individual patient records would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

In addition, it would not be appropriate to search through individual patient records for the purposes for responding to a FOI request, there would be no patient expectation that medical records would be used in this way.

Furthermore, under Section 16 of the Freedom of Information Act, we can advise that it would require an extensive manual review of all admissions just to ascertain if information relevant to your request is held. As such, we advise that there is no way to refine this request to bring it within the appropriate limit.

Q7. How many patients were treated for Colorectal Cancer (ICD-10 codes C18*, C19*, C20*, D010, D011, D012) with the following combinations or chemotherapy and other agents in the 3 months between the start of January 2026 and end of March 2026, or latest 3-month period available?

Name of chemotherapy combination		Number patients with CRC treated
7.1 Bevacizumab + Trifluridine + Tipiracil		

7.2 Bevacizumab + FOLFOX		
7.3 Bevacizumab + FOLFIRI		
7.4 Cetuximab + FOLFIRI		
7.5 Cetuximab + FOLFOX		
7.6 Cetuximab + FOLFIRINOX / FOLFOXIRI		
7.7 Cetuximab Monotherapy		
7.8 Panitumumab + FOLFIRI		
7.9 Panitumumab + FOLFOX		
7.10 Panitumumab + FOLFIRINOX / FOLFOXIRI		
7.11 Capecitabine + Oxaliplatin (XELOX)		
7.12 Capecitabine + Irinotecan (XELIRI)		

Response: This information is not recorded centrally and therefore retrieving it would involve a manual search of individual patient records. As such we cannot provide this information as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of individual patient records would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

In addition, it would not be appropriate to search through individual patient records for the purposes for responding to a FOI request, there would be no patient expectation that medical records would be used in this way.

Furthermore, under Section 16 of the Freedom of Information Act, we can advise that it would require an extensive manual review of all admissions just to ascertain if information relevant to your request is held. As such, we advise that there is no way to refine this request to bring it within the appropriate limit.

Email: Foi.Team@Southerntrust.hscni.net